Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication

被引：5

作者：

Kobayashi, Kazuo ^{[1
,20
]}

Toyoda, Masao ^{[2
]}

Tone, Atsuhito ^{[3
]}

Kawanami, Daiji ^{[4
]}

Suzuki, Daisuke ^{[5
]}

Tsuriya, Daisuke ^{[6
]}

Machimura, Hideo ^{[7
]}

Shimura, Hidetoshi ^{[8
]}

Takeda, Hiroshi ^{[9
]}

Yokomizo, Hisashi ^{[4
]}

Takeshita, Kei ^{[6
]}

Chin, Keiichi ^{[10
]}

Kanasaki, Keizo ^{[11
]}

Miyauchi, Masaaki ^{[12
]}

Saburi, Masuo ^{[13
]}

Morita, Miwa ^{[11
]}

Yomota, Miwako ^{[11
]}

Kimura, Moritsugu ^{[2
]}

Hatori, Nobuo ^{[14
]}

Nakajima, Shinichi ^{[15
]}

Ito, Shun ^{[16
]}

Tsukamoto, Shunichiro ^{[1
]}

Murata, Takashi ^{[17
]}

Matsushita, Takaya ^{[13
]}

Furuki, Takayuki ^{[18
]}

Hashimoto, Takuya ^{[6
]}

Umezono, Tomoya ^{[19
]}

Muta, Yoshimi ^{[4
]}

Takashi, Yuichi ^{[4
]}

Tamura, Kouichi ^{[1
]}

机构：

[1] Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, Yokohama, Japan

[2] Tokai Univ, Sch Med, Dept Internal Med, Div Nephrol Endocrinol & Metab, Isehara, Japan

[3] Okayama Saiseikai Gen Hosp, Diabet Ctr, Dept Internal Med, Okayama, Japan

[4] Fukuoka Univ, Sch Med, Dept Endocrinol & Diabet Mellitus, Fukuoka, Japan

[5] Suzuki Diabet Clin, Atsugi, Japan

[6] Hamamatsu Univ, Sch Med, Dept Internal Med 2, Div Endocrinol & Metab, Hamamatsu, Japan

[7] Machimura internal Med Clin, Hiratuska, Japan

[8] Shimura Clin, Sagamihara, Japan

[9] Takeda Clin, Isehara, Japan

[10] Hakuai Clin, Sagamihara, Japan

[11] Shimane Univ, Fac Med, Dept Internal Med 1, Endocrinol & Metab, Izumo, Japan

[12] Miyauchi Diabet Clin, Hadano, Japan

[13] Tokyo Med Univ, Hachioji Med Ctr, Dept Diabetol Endocrinol & Metab, Hachioji, Japan

[14] Kobayashi Hosp, Odawara, Japan

[15] Sagami Junkanki Clin, Sagamihara, Japan

[16] Sagamihara Red Cross Hosp, Dept Internal Med, Sagamihara, Japan

[17] Natl Hosp Org Kyoto Med Ctr, Diabet Ctr, Dept Clin Nutr, Kyoto, Japan

[18] Hadano Stn south gate Clin, Hadano, Japan

[19] Umezono Internal Med Clin, Atsugi, Japan

[20] Yokohama City Univ, Grad Sch Med, Dept Med Sci & Cardiorenal Med, 3-9 Fukuura Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan

来源：

DIABETES & VASCULAR DISEASE RESEARCH | 2023年 / 20卷 / 06期

基金：

日本学术振兴会;

关键词：

Sodium-glucose cotransporter 2 inhibitors; glucagon-like peptide 1 receptor agonist; renal outcome; combination treatment; preceding drug; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE; KIDNEY;

D O I：

10.1177/14791641231222837

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AimsCombination therapy with sodium-glucose cotransporter inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1Ras) is now of interest in clinical practice. The present study evaluated the effects of the preceding drug type on the renal outcome in clinical practice.MethodsWe retrospectively extracted type 2 diabetes mellitus patients who had received both SGLT2i and GLP1Ra treatment for at least 1 year. A total of 331 patients in the GLP1Ra-preceding group and 312 patients in the SGLT2i-preceding group were ultimately analyzed. Either progression of the albuminuria status and/or a >= 30% decrease in the eGFR was set as the primary renal composite outcome. The analysis using propensity score with inverse probability weighting was performed for the outcome.ResultsThe incidences of the renal composite outcome in the SGLT2i- and GLP1Ra-preceding groups were 28% and 25%, respectively, with an odds ratio [95% confidence interval] of 1.14 [0.75, 1.73] (p = .54). A logistic regression analysis showed that the mean arterial pressure (MAP) at baseline, the logarithmic value of the urine albumin-to-creatinine ratio at baseline, and the change in MAP were independent factors influencing the renal composite outcome.ConclusionWith combination therapy of SGLT2i and GLP1Ra, the preceding drug did not affect the renal outcome.

引用

页数：8

共 28 条

[1] Analysis of partially observed clustered data using generalized estimating equations and multiple imputation
Aloisio, Kathryn M.
Micali, Nadia
Swanson, Sonja A.
Field, Alison
Horton, Nicholas J.
[J]. STATA JOURNAL, 2014, 14 (04) : 863 - 883
[2] Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Austin, Peter C.
[J]. PHARMACEUTICAL STATISTICS, 2011, 10 (02) : 150 - 161
[3] Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
Cherney, David Z. I.
Perkins, Bruce A.
Soleymanlou, Nima
Maione, Maria
Lai, Vesta
Lee, Alana
Fagan, Nora M.
Woerle, Hans J.
Johansen, Odd Erik
Broedl, Uli C.
von Eynatten, Maximilian
[J]. CIRCULATION, 2014, 129 (05) : 587 - 597
[4] DBR, 1987, Multiple imputation for nonresponse in surveys
[5] Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
DeFronzo, Ralph A.
[J]. DIABETES OBESITY & METABOLISM, 2017, 19 (10) : 1353 - 1362
[6] The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, Daniel J.
[J]. CELL METABOLISM, 2016, 24 (01) : 15 - 30
[7] Enders C. K., 2010, Applied Missing Data Analysis
[8] Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Gerstein, Hertzel C.
Sattar, Naveed
Rosenstock, Julio
Ramasundarahettige, Chinthanie
Pratley, Richard
Lopes, Renato D.
Lam, Carolyn S. P.
Khurmi, Nardev S.
Heenan, Laura
Del Prato, Stefano
Dyal, Leanne
Branch, Kelley
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10) : 896 - 907
[9] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, Hiddo J. L.
Kosiborod, Mikhail
Inzucchi, Silvio E.
Cherney, David Z. I.
[J]. KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
[10] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Hernandez, Adrian F.
Green, Jennifer B.
Janmohamed, Salim
D'Agostino, Ralph B., Sr.
Granger, Christopher B.
Jones, Nigel P.
Leiter, Lawrence A.
Rosenberg, Anne E.
Sigmon, Kristina N.
Somerville, Matthew C.
Thorpe, Karl M.
McMurray, John J. V.
Del Prato, Stefano
[J]. LANCET, 2018, 392 (10157) : 1519 - 1529

← 1 2 3 →